Monoclonal Antibody ER MPT Film
The aim of this study is to develop and evaluate a monoclonal antibody-based extended-release (ER) multipurpose prevention technology (MPT) vaginal film that provides up to 7 days of protection against unintended pregnancy, HIV, and HSV from a single application.
For more information, contact: Lisa Rohan at lrohan@mwri.magee.edu
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Topical - Film - Vaginal
Developer:
- Magee-Women's Research Inst. & Foundation
- University of Pittsburgh
Funding:
- National Institutes of Health (NIH)
- R33
Funding Mechanism:
R33 funded
Past Funding:
NICHD R61
Active Ingredient(s):
- Monoclonal Antibodies
Product Indication(s):
- HIV
- HSV-2
- Unintended Pregnancy